Attention Deficit Hyperactivity Disorder Adhd — Patent Landscape
1
Approved drugs
12
Active US patents
57/100
Avg vulnerability
—
Annual revenue covered
Originators in Attention Deficit Hyperactivity Disorder Adhd
Cliff calendar — next 15 years
8
33
Approved drugs ranked by patent estate
| Drug | Originator | Active patents | Avg vuln | Revenue | First cliff |
|---|---|---|---|---|---|
| DEXTROAMPHETAMINE | — | 12 | 57 | — | 2033-10-24 |
Most attackable patents
| Patent | Drug | Type | Vuln | Expiry |
|---|---|---|---|---|
| 9456993 | DEXTROAMPHETAMINE | method of use | 70 | 2033-10-24 |
| 9456993 | DEXTROAMPHETAMINE | method of use | 70 | 2033-10-24 |
| 9456993 | DEXTROAMPHETAMINE | method of use | 70 | 2033-10-24 |
| 9456993 | DEXTROAMPHETAMINE | method of use | 70 | 2033-10-24 |
| 9474722 | DEXTROAMPHETAMINE | formulation | 50 | 2033-10-24 |
| 9474722 | DEXTROAMPHETAMINE | formulation | 50 | 2033-10-24 |
| 9474722 | DEXTROAMPHETAMINE | formulation | 50 | 2033-10-24 |
| 9474722 | DEXTROAMPHETAMINE | formulation | 50 | 2033-10-24 |
| 11559501 | DEXTROAMPHETAMINE | formulation | 50 | 2042-01-06 |
| 11559501 | DEXTROAMPHETAMINE | formulation | 50 | 2042-01-06 |
Strongest defences
| Patent | Drug | Type | Vuln | Expiry |
|---|---|---|---|---|
| 11559501 | DEXTROAMPHETAMINE | formulation | 50 | 2042-01-06 |
| 11559501 | DEXTROAMPHETAMINE | formulation | 50 | 2042-01-06 |
| 11559501 | DEXTROAMPHETAMINE | formulation | 50 | 2042-01-06 |
| 11559501 | DEXTROAMPHETAMINE | formulation | 50 | 2042-01-06 |
| 9474722 | DEXTROAMPHETAMINE | formulation | 50 | 2033-10-24 |
| 9474722 | DEXTROAMPHETAMINE | formulation | 50 | 2033-10-24 |
| 9474722 | DEXTROAMPHETAMINE | formulation | 50 | 2033-10-24 |
| 9474722 | DEXTROAMPHETAMINE | formulation | 50 | 2033-10-24 |
| 9456993 | DEXTROAMPHETAMINE | method of use | 70 | 2033-10-24 |
| 9456993 | DEXTROAMPHETAMINE | method of use | 70 | 2033-10-24 |
Related
- Attention Deficit Hyperactivity Disorder Adhd — full disease profile
- AI Patent Landscape Report — type "attention deficit hyperactivity disorder adhd " for an AI exec memo
- Company Patent Rankings
- Biosimilar Opportunity Scanner